MedTrace Logo

Effectiveness of a Bivalent Killed Whole Cell Based Oral Cholera Vaccine

NCT01508507 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2013-06-05

No results posted yet for this study

Summary

Various field studies has found that the modified , bivalent, whole cell - based oral cholera vaccine (OCV) to be safe, immunogenic and effective with protective efficacy of 67 % in earlier clinical trials. However, the effectiveness of the vaccine in "real" life situation using the public health system is unknown. It is critical to follow up in the same population, where pilot introduction of OCV was introduced and evaluate vaccine proactive effectiveness at individual as well as at population level. The follow - up and determination of effectiveness of mass OCV vaccination was requested by State Government.

Conditions

  • Cholera

Sponsors & Collaborators

  • Department of Health and Family Welfare, Orissa

    collaborator OTHER

  • Regional Medical Research Center, Orissa

    collaborator UNKNOWN

  • International Vaccine Institute

    lead OTHER

Principal Investigators

  • Shantanu K Kar, MD · Director, Regional Medical Research Center, Bhubanewar, Orissa, India

  • Thomas F Wierzba, PHD · International Vaccine Institute

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • India

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01508507 on ClinicalTrials.gov